Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.51 |
| ▸ | PARP1 | P09874 | 6/20 | 0.51 |
| ▸ | PARP11 | Q9NR21 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15466514 | 0.81 | PARP10 (0.62) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL30669000 | 0.81 | PARP10 (0.47) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL26671057 | 0.81 | PARP10 (0.47) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL26670926 | 0.77 | PARP10 (0.43) | PARP10PARP1PARP11KDM4EF7 | |
| SCHEMBL27403164 | 0.76 | MAP4K1 (0.46) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL24680794 | 0.76 | PARP10 (0.56) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL14991814 | 0.76 | PARP10 (0.56) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL12559528 | 0.76 | GRM5 (0.59) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL20572003 | 0.72 | PARP10 (0.56) | PARP10PARP1PARP11KDM4EGRM5 | |
| SCHEMBL17073495 | 0.72 | PARP10 (0.56) | PARP10PARP1PARP11KDM4EGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667989-A4 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARM INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1667989-A1 | SUBSTITUTED ISOQUINOLINONES | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | PARP10 16/4885PARP1 15/4885PARP11 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.